Crohn's Disease and Colitis Trial, Recruiting NCT06581042 Sponsor: AbbVie Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, Recruiting

NCT06581042
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with moderate to severe Crohn's disease or Ulcerative colitis, and who started taking upadacitinib at least 12 months before joining the study — including those who later stopped taking it or switched to a different treatment
  • People for whom a doctor has decided, as part of their normal medical care, to prescribe the commercially available form of upadacitinib — and where that decision was made before and separately from any involvement in this study
  • People who have been prescribed upadacitinib in line with the officially approved guidelines and treatment recommendations in their country

Who may not be able to join:

  • People who have previously taken upadacitinib as part of a clinical trial or an early access program
  • People who are currently taking part in another interventional research study (studies that are observational only may not be affected — confirm with trial site)
  • People who have a stoma (a surgically created opening in the abdomen used to redirect waste)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: ABBVIE INC., AbbVie

Phone: 844-663-3742

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
27 September 2024
Est. completion
1 September 2029

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Percentage of Participants Achieving Clinical Remission as per Partial Adapted Mayo Subscores for Ulcerative Colitis; Percentage of Participants Achieving Clinical Remission as per Patient Reported Outcome (PRO2) for Crohn's Disease

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov